Skip to content

Reference information only. Therapept does not sell peptides and does not provide medical advice.Research-use notice

Therapept

Stack · Skin / cosmetic

GHK-Cu in cosmetic combinations

Copper tripeptide-1 appears in topical formulations alongside matrix-support ingredients (retinoids, niacinamide, other signal peptides). Cosmetic formulation is a different regulatory world from injectable use — the FDA compounding entry for injectable GHK-Cu was withdrawn, while topical INCI use is a normal cosmetic-ingredient path.

Compounds

  • GHK-Cu

    Copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine

    No FDA-approved product

Why people combine them

Copper tripeptide-1 appears in topical formulations alongside matrix-support ingredients (retinoids, niacinamide, other signal peptides). Cosmetic formulation is a different regulatory world from injectable use — the FDA compounding entry for injectable GHK-Cu was withdrawn, while topical INCI use is a normal cosmetic-ingredient path.

Evidence for the combination

Discussed in published sources

The review discusses GHK's reported actions in dermal research contexts; it is a narrative review from the originating laboratory, not a trial of cosmetic combinations. Pickart and Margolina, Int J Mol Sci (2018) — PubMed 29986520

Evidence for each component

  • GHK-Cu — Dermal/cellular research corpus; cosmetic ingredient (INCI Copper Tripeptide-1); injectable compounding nomination withdrawn by FDA.

Commonly reported dosing and protocols

Displayed source by source. Therapept does not compose these into a recommended protocol.

  • INDUSTRYCosmetic formulation literature and product labelling

    Topical products list Copper Tripeptide-1 at cosmetic-use concentrations on their INCI labels; published clinical comparisons of combinations are scarce.

    Included to distinguish regulated topical cosmetic use from unregulated injectable use.

    Checked 17 September 2026

Potential overlap and concerns

  • Injectable GHK-Cu sits on FDA's withdrawn-nominations table scoped to injectable routes; topical cosmetic use is a separate, lawful category that says nothing about injectable safety.

What is known

  • Copper Tripeptide-1 is an established cosmetic ingredient.
  • The injectable route is the subject of a withdrawn FDA compounding nomination.

What is speculative

  • Claims that specific ingredient pairings outperform single-ingredient products.

Sources

  1. FDA — Certain bulk drug substances for use in compounding may present significant safety risks

Last reviewed 17 September 2026 · Compiled by Therapept Editorial · How these records are built